Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized double-blind placebo-controlled study of CRD-740 in chronic heart failure
MOH_2022-06-22_011849Phase 2Not yet recruiting
- Sponsor
- Cardurion Pharmaceuticals
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of edelinontrine in chronic heart failure (CHF) (4 arms), sponsored by Cardurion Pharmaceuticals. Planned start May 2022; status: not yet recruiting.
02
Drugs
edelinontrine
03
Conditions
chronic heart failure (CHF)
Beyond the preview
Go deeper on MOH_2022-06-22_011849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-06-22_011849.